Study: First Test for Colon Cancer Recurrence

Researchers from the University of Oxford announced on Thursday that they have developed the first genetic test for predicting the likelihood that a patient’s colon cancer will recur. The test, which scans for mutations in 12 genes expressed by colon tumors, can tell patients in the early stages of colon cancer the chances that their disease will come back after treatment.

Share

Explainer: Why was Intel fined?

The European Commission handed down its ruling in a landmark anti-trust case against Intel Wednesday, fining the computer chip giant a record $1.45 billion for abusing its dominant position in the computer processing unit (CPU) market. The ruling, which Intel plans to appeal, may have future implications for American companies accused of “jurisdiction shopping” to avoid anti-trust verdicts against them, says CNN’s Jim Boulden, who explains the basics of the Intel case

Share

ACLU sues over patents on breast cancer genes

Patents on two human genes linked to breast and ovarian cancers are being challenged in court by the American Civil Liberties Union, which argues that patenting pure genes is unconstitutional and hinders research for a cancer cure. “Knowledge about our own bodies and the ability to make decisions about our health care are some of our most personal and fundamental rights,” said ACLU Executive Director Anthony D. Romero.

Share

Woods seven shots off the pace at TPC

Tiger Woods is seven shots off the lead after the second day of the Players Championship, with German Alex Cejka’s 5-under 67 putting him clear of the chasing field. Cejka, who has not won a tournament on the PGA Tour, leads Ian Poulter by two shots with a group of six players featuring this year’s Masters winner Angel Cabrera and the American Kevin Na two shots further back

Share

Why Antidepressants Don’t Live Up to the Hype

In the ’90s, Americans grew fond of the idea that you can fix depression simply by taking a pill — most famously fluoxetine , though fluoxetine is just one of at least seven selective serotonin reuptake inhibitors that have been prescribed to treat hundreds of millions of people around the world. But in the past few years, researchers have challenged the effectiveness of Prozac and other SSRIs in several studies. For instance, a review published in the Journal of Affective Disorders in February attributed 68% of the benefit from antidepressants to the placebo effect

Share